Money Talks: Why weight-loss drugs will resha...

When Alexis de Tocqueville visited America from France in 1831 he saw a new kind of society. Not just a country, but an idea that would change the world. His book “Democracy in America” was a big influence on later generations of writers and thinkers, including The Economist’s US ...  Show more

Join The Economist’s Mike Bird, Alice Fulwood and Ethan Wu for award-winning reporting and discussion on the stories that move markets. They speak to top bosses, investors and analysts around the world for unmatched insight into global finance, business and economics. Published e ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ...  Show more

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ...  Show more

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more

Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ...  Show more